JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

MAY 1 2 2005

FILED CLERK'S OFFICE

DOCKET NO. 1456

BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE **LITIGATION**

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO-21)

On April 30, 2002, the Panel transferred 16 civil actions to the United States District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. Since that time, 35 additional actions have been transferred to the District of Massachusetts. With the consent of that court, all such actions have been assigned to the Honorable Patti B. Saris.

It appears that the actions on this conditional transfer order involve questions of fact which are common to the actions previously transferred to the District of Massachusetts and assigned to Judge Saris.

Pursuant to Rule 7.4 of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation, 199 F.R.D. 425, 435-36 (2001), these actions are transferred under 28 U.S.C. § 1407 to the District of Massachusetts for the reasons stated in the order of April 30, 2002, 201 F.Supp.2d 1378 (J.P.M.L. 2002), and, with the consent of that court, assigned to the Honorable Patti B. Saris.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of Massachusetts. The transmittal of this order to said Clerk shall be stayed fifteen (15) days from the entry thereof and if any party files a notice of opposition with the Clerk of the Panel within this fifteen (15) day period, the stay will be continued until further order of the Panel

Inasmuch as no objection is pending at this time, the stay is lifted. MAY 3 1 2005 **CLERK'S OFFICE** JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

FOR THE PANEL:

Clerk of the Panel

SCHEDULE CTO-21 - TAG-ALONG ACTIONS DOCKET NO. 1456 IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

DIST. DIV. C.A. #	CASE CAPTION
NEW YORK NORTHERN	
NYN 1 05-408	The County of Washington v. Abbott Laboratories, Inc., et al.
NYN 1 05-422	County of Rensselaer v. Abbott Laboratories, Inc., et al.
NYN 1 05-425	County of Albany v. Abbott Laboratories, Inc., et al.
NYN 1 05-468	County of Warren v. Abbott Laboratories, Inc., et al.
NYN 1 05-474	County of Greene v. Abbott Laboratories, Inc., et al.
NYN 1 05-478	County of Saratoga v. Abbott Laboratories, Inc., et al.
NYN 3 05-354	County of Chenango v. Abbott Laboratories, Inc., et al.
NYN 3 05-456	The County of Broome v. Abbott Laboratories, Inc., et al.
NYN 5 05-397	County of Tompkins v. Abbott Laboratories, Inc., et al.
NYN 5 05-423	County of Cayuga v. Abbott Laboratories, Inc., et al.
NYN 6 05-415	County of Herkimer, New York v. Abbott Laboratories, Inc., et al.
NYN 6 05-489	County of Oneida v. Abbott Laboratories, Inc., et al.
NYN 7 05-479	County of Saint Lawrence v. Abbott Laboratories, Inc., et al.
NEW YORK WESTERN	
NYW 1 05-214	County of Chautaugua v. Abbatt of Laboratorias Inc. et al.
NYW 1 05-214 NYW 1 05-236	County of Chautauqua v. Abbott of Laboratories, Inc., et al.
NYW 1 05-256	County of Allegany v. Abbott Laboratories, Inc., et al.
	County of Cattaraugus v. Abbott Laboratories, Inc., et al.
NYW 1 05-259	County of Erie v. Abbott Laboratories, Inc., et al. Opposed 5/24/05
NYW 6 05-6138	County of Wayne v. Abbott Laboratories, et al.
NYW 6 05-6148	County of Monroe v. Abbott Laboratories, Inc., et al.
NYW 6 05-6172	County of Yates v. Abbott Laboratories, Inc., et al.

U.S. District Court Northern District of New York [LIVE - Version 2.4] (Syracuse) CIVIL DOCKET FOR CASE #: 5:05-cv-00423-NAM-GJD

County of Cayuga v. Abbott Laboratories, Inc. et al

Assigned to: Judge Norman A. Mordue

Referred to: Magistrate Judge Gustave J. DiBianco

Cause: 42:1396 - Tort Negligence

Date Filed: 04/06/2005 Jury Demand: Plaintiff

Nature of Suit: 890 Other Statutory

Actions

Jurisdiction: Federal Question

Plaintiff

County of Cayuga

represented by Aaron D. Hovan

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: ahovan@kmslaw.com

LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Joanne M. Cicala

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600 Fax: 212-751-2540 Email: jcicala@kmslaw.com LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Roger W. Kirby

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600

Fax: 212-751-2540

Email: iramirez@kmslaw.com


LEAD ATTORNEY

ATTORNEY TO BE NOTICED

٧.

Defendant

Abbott Laboratories, Inc.



Boehringer Ingelheim Corp.

Defendant

Boehringer Ingelheim

Pharmaceuticals, Inc.

Defendant

Bristol-Meyers Squibb Company

Defendant

Dermik Laboratories, Inc.

Defendant

Dey, Inc.

Defendant

Eisai, Inc.

Defendant

Eli Lilly and Company

Defendant

Endo Pharmaceuticals, Inc.

Defendant

Ethex Corp.

Defendant

Forest Laboratories, Inc.

Defendant

Forest Pharmaceuticals, Inc.

Defendant

Fujisawa Healthcare, Inc.

Defendant

Fujisawa USA, Inc.

Defendant

Genentech, Inc.

Defendant

Genzyme Corp.

•	<u>Defendant</u>
•	Gilead Sciences, Inc.
]	<u>Defendant</u>
(Glaxosmithkline, P.L.C.
]	<u>Defendant</u>
(Greenstone, Ltd.
]	<u>Defendant</u>
]	Hoffman-La Roche, Inc.
]	Defendant
]	Immunex Corp.
<u>]</u>	<u>Defendant</u>
]	Ivax Corp.
]	<u>Defendant</u>
]	Ivax Pharmaceuticals, Inc.
]	<u>Defendant</u>
•	Janssen Pharmaceutica Products, LP
]	<u>Defendant</u>
•	Johnson & Johnson
]	<u>Defendant</u>
]	King Pharmaceuticals, Inc.
ļ	<u>Defendant</u>
I	McNeil-PPC, Inc.
]	<u>Defendant</u>
ľ	Medimmune, Inc.
]	<u>Defendant</u>
ľ	Merck & Co., Inc.
Ţ	<u>Defendant</u>
ľ	Monarch Pharmaceuticals, Inc.
_	De <u>fendant</u>

Mylan Laboratories, Inc.

Mylan Pharmaceuticals, Inc.

Defendant

Novartis Pharmaceuticals Corp.

Defendant

Novo Nordisk Pharmaceuticals, Inc.

Defendant

Oncology Therapeutics Network

Corp.

Defendant

Organon Pharmaceuticals USA, Inc.

Defendant

Ortho Biotech Products LP

Defendant

Ortho-McNeil Pharmaceutical, Inc.

Defendant

Par Pharmaceutical, Inc.

Defendant

Pfizer, Inc.

Defendant

Pharmacia Corp.

Defendant

Purdue Pharma, L.P.

Defendant

Purepac Pharmaceutical Co.

Defendant

Reliant Pharmaceuticals

Defendant

Roche Laboratories, Inc.

Defendant

Roxane Laboratories, Inc.

ECF I	TABLE - C.S. CONSIGNATION OF A MAD CONTRACT CONT
	<u>Defendant</u>
	Sandoz, Inc.
	Defendant
	Sanofi-Synthelabo, Inc.
	<u>Defendant</u>
	Schering Corp.
	<u>Defendant</u>
	Schering-Plough Corp.
	<u>Defendant</u>
	Serono, Inc.
	<u>Defendant</u>
	Smithklinebeecham Corp. doing business as

Glaxosmithkline

Takeda Pharmaceuticals North America, Inc.

Defendant

Tap Pharmaceutical Products, Inc.

Defendant

Teva Pharmaceutical USA, Inc.

Defendant

UCB Pharma, Inc.

Defendant

UDL Laboratories, Inc.

Defendant

Warrick Pharmaceuticals Corp.

Defendant

Watson Pharma, Inc.

Defendant

Watson Pharmaceuticals, Inc.

Wyeth

Date Filed #		Docket Text		
04/06/2005	1	COMPLAINT against Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Baxter Healthcare Corporation, Baxter International, Inc., Bayer Corp., Ben Venue Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Schering Corp., Abbott Laboratories, Inc., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Warrick Pharmaceuticals Corp., Agouron Pharmaceuticals, Inc., Watson Pharma, Inc., Watson Pharma, Inc., Watson Pharma, Inc., Watson Pharma, Inc., Watson Pharmaceuticals, Inc., Weth, Alcon Laboratori		
04/06/2005		Summons Issued as to Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Baxter Healthcare Corporation, Baxter International, Inc., Bayer Corp., Ben Venue Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Gilead Sciences, Inc., Glaxosmithkline,		

		P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, Inc., McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Schering Corp., Abbott Laboratories, Inc., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Warrick Pharmaceuticals Corp., Agouron Pharmaceuticals, Inc., Watson Pharma, Inc., Watson Pharmaceuticals, Inc., Wyeth, Alcon Laboratories, Inc., Allergan, Inc., (wjg,) (Entered: 04/06/2005)	
04/06/2005	2	G.O. 25 FILING ORDER ISSUED Initial R16 Conference set for 8/4/2005 02:30 PM in Syracuse before Magistrate Judge Gustave J. DiBianco. Civil Case Management Plan due by 7/22/2005. (wjg,) (Entered: 04/06/2005)	
05/03/2005	3	Letter from Aaron Hovan, outside counsel for County of Cayuga requesting Adjournment of Deadlines. (Hovan, Aaron) (Entered: 05/03/2005)	
05/05/2005	4	LETTER/REQUEST AND ORDER; Letter addressed to MJ DiBianco requesting that the Civil case managment plan and Rule 16 conference be postponed as this case has been transferred to M.D.L.; So Ordered, Court's order setting forth deadlines for submission of a civil case mgm't plan is vacated, Rule 16 conference cancelled; Parties to file a Status report by 12/15/05. Signed by Judge Gustave J. DiBianco on 5/4/05. (kcl,) (Entered: 05/05/2005)	
05/05/2005	·	Set/Reset Deadlines: Status Report due by 12/15/2005. (kcl,) (Entered: 05/05/2005)	
05/19/2005	<u>5</u>	NOTICE from Judicial panel on multidistrict litigation advising of Conditional transfer Order (kcl,) (Entered: 05/19/2005)	

PACER Service Center

Transaction Receipt

06/07/2005 15:59:43

PACER Login:	us2510	Client Code:	
Description:	Docket Report	Search Criteria:	5:05-cv-00423-NAM-GJD
Billable Pages:	4	Cost:	0.32